France- and US-based ag biotech company Micropep is closer to commercializing its peptide-based biofungicide Promisin after making regulatory submissions in the United States and the European Union this week.
The submissions come on the heels of Promisin submissions in Paraguay and Brazil, and send “an important signal to external stakeholders,” says Micropep VP of regulatory Dr. Kevin Leiner.
“It’s a really strong proof point for the capabilities of Micropep and for the ability of our Krisalix discovery platform to advance interesting product candidates and de-risk them to the point where we can get them on the market and provide a valuable tool to the farmer.”
Promisin is the first product to come out of Krisalix, the company’s AI-based discovery platform platform, which uses computational biology, AI, and formulation science to discover the best micro-peptide sequences for crop protection.
According to Leiner, regulatory submissions for the product also mark the company’s shift from a research and discovery entity to one truly readying itself for launch in commercial markets.
Fighting fungicide resistance with peptides
Promisin relies on a novel biological mode of action to fight fungal diseases in crops, and is designed to complement existing fungicide tools rather than replace them outright, says Leiner. It is particularly useful in managing fungicide resistance, which has steadily risen since the 1970s.
The bulk of conventional fungicides are site-specific, meaning they target one single metabolic pathway. A single genetic mutation in that pathway, such as one amino acid in the protein, can reduce a fungus’s sensitivity to a chemical and render it ineffective.
Promisin is in a class of peptides that acts by disrupting cell membranes rather than binding to a specific target, says Leiner. Because of that, “It would be very difficult for an organism to evolve resistance to Promisin peptides.”
This class of peptides also complements existing pest management strategies, he adds. Promisin mixes well with other solutions in the tank, allowing farmers to hit targets with multiple modes of action, which also addresses and lessen the chance of resistance developing.
“[For] what is lost against a conventional fungicide. Promisin can come in and and essentially clean up the resistant strains.”
Outside of resistance management, Promisin has already shown strong efficacy in hundreds of field trials around the world over multiple years, says Leiner, who adds that there is a “highly favorable safety and sustainability profile” in play too.
“We don’t see significant concern with non-target organisms. From a human and environmental safety perspective, it’s fantastic. From a sustainability perspective, we’re not worried about persistence in the environment, the way you may be with some small molecule conventional pesticides. We’re not worried about residues or having to establish tolerances or maximum residue limits.”
Towards commercialization
Leiner joined Micropep a few years ago, when it was essentially a discovery and research company “with an almost academic feel.”
“These regulatory submissions really are the the milestone where we can say, okay, this development stage for the initial crops is now complete. Now we start our pre-commercial phase.”
Soybeans are a key export in Paraguay and Brazil, and Micropep will focus on that and other row crops for those markets. In particular, it is targeting Phakopsora pachyrhizi (Asian soybean rust), Corynespora cassiicola (Target Spot), and Cercospora kikuchii (Leaf Blight).
Row crops will also be a focus area in the US along with grapevines and potatoes. In Europe, which produces significantly fewer soybeans, Micropep will work mostly in grapevines and potatoes.
Last year saw Micropep appoint new CEO Georg Goeres, who previously ran the biologicals unit of Indigo Ag and will lead Micropep’s efforts to commercialization.
Regulatory evaluations and approvals for Promisin will vary in terms of timeline based on the region. Brazil, for example, has a notably faster approval timeline than the European Union—around 18 months versus a few years, respectively.
In the meantime, Micropep will “prepare the ground” for product launches, says Leiner. “We will make sure the supply chain is established, distribution relationships are established, and that way, when we have the market authorizations in each country, we’ll be ready to hit the ground running.”
The company will continue to work on fungicides but will also look for new peptides that could work as herbicides and insecticides.
Facts Only
* Micropep submitted regulatory applications for Promisin in the United States and the European Union this week.
* The company previously submitted Promisin in Paraguay and Brazil.
* Promisin is a product derived from the Krisalix AI-based discovery platform.
* The Krisalix platform uses computational biology, AI, and formulation science to discover micro-peptide sequences for crop protection.
* Micropep views the regulatory submissions as a milestone moving from research to pre-commercial phase.
* Promisin relies on disrupting cell membranes rather than binding to specific targets.
* This mechanism is intended to reduce resistance development against fungal diseases.
* Field trials have shown strong efficacy in hundreds of field trials globally over multiple years.
* The company reports a highly favorable safety and sustainability profile regarding non-target organisms and environmental persistence.
* Target crops include soybeans in Paraguay and Brazil, and grapevines and potatoes in Europe.
Executive Summary
Micropep, a France- and US-based ag biotech company, recently submitted regulatory applications for its peptide-based biofungicide Promisin in the United States and the European Union. These submissions follow prior filings in Paraguay and Brazil. The company's VP of regulatory affairs stated that these submissions signal a strong proof point regarding the capabilities of Micropep and its Krisalix discovery platform to advance product candidates toward market readiness. Promisin is derived from the Krisalix platform, an AI-based discovery system utilizing computational biology and AI to find micro-peptide sequences for crop protection. The company views these regulatory steps as a transition from a research entity to one preparing for commercial launch.
Promisin operates on a novel mode of action by disrupting cell membranes rather than targeting specific metabolic pathways, which is intended to combat fungicide resistance that has increased since the 1970s. This mechanism suggests potential benefits in managing resistance by allowing it to complement existing fungicide tools and mitigating the evolution of resistance against peptides. Furthermore, Promisin has demonstrated efficacy in field trials and possesses a favorable safety and sustainability profile with low concerns regarding non-target organisms or residue persistence compared to some conventional pesticides. The company is targeting specific crop diseases like Asian soybean rust, Target Spot, and Leaf Blight in key markets such as Paraguay, Brazil (soybeans), the US (soybeans, grapevines, potatoes), and Europe (grapevines, potatoes).
Full Take
The narrative positions the transition from academic discovery to commercial readiness as a core value proposition, leveraging AI-driven platform technology. The shift from a research entity to a launch-ready operator is framed not just as regulatory compliance but as validated capability. The mechanism of action for Promisin—membrane disruption rather than specific target binding—introduces a potent argument against resistance evolution by offering an alternative biochemical strategy that complements existing tools, which shifts the focus from simple efficacy to systemic resistance management.
The implication for the agrochemical landscape is that a novel mode of action based on physical disruption, supported by computational prediction, offers a path around the evolutionary pressures driving conventional resistance management. However, the claim regarding resistance reversal must be rigorously tested against long-term field data across diverse fungal strains and environmental conditions. The focus on sustainability and low residue concerns attempts to create an immediate bridge toward market acceptance, appealing to regulatory and public concerns outside of pure efficacy metrics. A crucial unstated element is the supply chain readiness; successful commercialization hinges as much on distribution and manufacturing scalability as it does on scientific novelty.
The pattern observed is the typical progression in biotechnology: successful discovery moves into formal validation (regulatory filings) which then precedes market access. The narrative successfully frames this sequence as a logical step toward de-risking investment. The potential manipulation lies in overstating the certainty of "de-risking" and equating regulatory submission with guaranteed market success, especially given the differing timelines for approval across jurisdictions like Brazil versus the EU. Further inquiry should focus on longitudinal data regarding resistance management effectiveness and the cost/benefit analysis for farmers when integrating this multi-modal approach. What are the established benchmarks for combining membrane disruption with existing fungicides in terms of practical field outcomes?
Sentinel — Human
This text reads like a detailed press release or earned media piece leveraging internal expertise, focusing on the specific scientific and regulatory milestones achieved by Micropep regarding Promisin.